+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Peripheral Neuropathy Treatment Market 2020-2026

  • ID: 5241108
  • Report
  • December 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Apotex, Inc.
  • Bristol Myers Squibb Co.
  • Cipla, Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline plc
Global Peripheral Neuropathy Treatment Market Size, Share & Trends Analysis Report, By Type (Antidepressants, Pain Relievers, Antiseizure, and Others), By Application (Diabetes, Chemotherapy-Induced, and Others) and Forecast, 2020-2026.

The global peripheral neuropathy treatment market is estimated to grow at a CAGR of 4.3% during the forecast period. The increasing prevalence of cancer is one of the major factors accelerating market growth. As per the World Health Organization (WHO), in 2018, 18.1 million new cancer incidences were reported globally. Globally, in 2018, 43.8 million persons were suffering from cancer who were diagnosed within the last 5 years. Rising cancer incidence has resulted in an increasing demand for chemotherapy to destroy rapidly growing cells in the body. However, some chemotherapy drugs may cause peripheral neuropathy, which is resulting in the demand for peripheral neuropathy treatment in which analgesics, antidepressants, or anticonvulsants, as well as topical numbing agents including lidocaine, are often used for the management of pain. Additionally, opioids may be used in cases that involve extreme pain.

The global peripheral neuropathy treatment market is segmented based on type and application. Based on type, the market is classified into antidepressants, pain relievers, antiseizure, and others. Based on the application, the market is classified into diabetes, chemotherapy-induced, and others. Diabetes is the most common form of neuropathic disorders, which is supporting the adoption of peripheral neuropathy treatment to manage diabetic peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. Therefore, increasing diabetes prevalence is one of the major causes leading to increasing demand for peripheral neuropathy treatment.

Geographically, Asia-Pacific is estimated to grow at the fastest CAGR during the forecast period owing to the rising prevalence of diabetes and cancer. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. In India, the number of new cancer incidences was 1.2 million in 2018. This may result in the demand for peripheral neuropathy treatment to treat nerve pain. The main drugs that are used for neuropathic pain include amitriptyline, duloxetine, gabapentin, and pregabalin.

Some prominent players in the market include Pfizer Inc., Grünenthal GmbH, Novartis International AG, Eli Lilly and Co., and Daiichi Sankyo Co. Ltd. Some strategic initiatives that are implemented by the market players include product launches and partnerships and collaborations. For instance, in November 2018, Grünenthal GmbH acquired a pharmaceutical firm based in the US, Averitas Pharma. This will enable Grünenthal to expand its geographical footprint in the US. Averitas Pharma will commercialize Qutenza (8 % capsaicin), the pain patch for Grünenthal in the US. This acquisition will enable Grünenthal to implement its growth strategy and enhancing its business across several geographies and pain-related therapeutic categories.

Research Methodology

The market study of the global peripheral neuropathy treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Peripheral Neuropathy Treatment Market Research and Analysis by Type
2. Global Peripheral Neuropathy Treatment Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the global peripheral neuropathy treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global peripheral neuropathy treatment market.
  • Insights about market determinants that are stimulating the global peripheral neuropathy treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Apotex, Inc.
  • Bristol Myers Squibb Co.
  • Cipla, Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline plc
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Grünenthal GmbH
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Novartis International AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Eli Lilly and Co.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Daiichi Sankyo Co. Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Peripheral Neuropathy Treatment Market by Type
5.1.1. Antidepressants
5.1.2. Pain Relievers
5.1.3. Antiseizure
5.1.4. Others
5.2. Global Peripheral Neuropathy Treatment Market by Application
5.2.1. Diabetes
5.2.2. Chemotherapy-Induced
5.2.3. Others

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Achelios Therapeutics, Inc.
7.2. Acorda Therapeutics, Inc.
7.3. Alembic Pharmaceuticals, Ltd.
7.4. Amneal Pharmaceuticals LLC
7.5. Apotex, Inc.
7.6. Assertio Therapeutics, Inc.
7.7. Bristol Myers Squibb Co.
7.8. Cipla, Ltd.
7.9. Daiichi Sankyo Company, Ltd.
7.10. Eli Lilly and Co.
7.11. GlaxoSmithKline plc
7.12. Glenmark Pharmaceuticals, Ltd.
7.13. Grünenthal GmbH
7.14. Innovus Pharmaceuticals, Inc.
7.15. Johnson & Johnson Services, Inc.
7.16. Lupin, Ltd.
7.17. Mylan N.V.
7.18. Novartis International AG
7.19. Pfizer, Inc.
7.20. Teva Pharmaceutical Industries, Ltd.
Note: Product cover images may vary from those shown
  • Achelios Therapeutics, Inc.
  • Acorda Therapeutics, Inc.
  • Alembic Pharmaceuticals, Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex, Inc.
  • Assertio Therapeutics, Inc.
  • Bristol Myers Squibb Co.
  • Cipla, Ltd.
  • Daiichi Sankyo Company, Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals, Ltd.
  • Grünenthal GmbH
  • Innovus Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries, Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll